Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week, Prospective Study Assessing the Efficacy of Tadalafil Monotherapy and Associations between Changes in Subjective Overactive Bladder Symptoms and Changes in Oxidative Stress in Patients with Lower Urinary Tract Symptoms

Trial Profile

A 12-week, Prospective Study Assessing the Efficacy of Tadalafil Monotherapy and Associations between Changes in Subjective Overactive Bladder Symptoms and Changes in Oxidative Stress in Patients with Lower Urinary Tract Symptoms

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Lower urinary tract symptoms; Overactive bladder
  • Focus Therapeutic Use

Most Recent Events

  • 28 Sep 2018 New trial record
  • 31 Aug 2018 Results presented at the 48th Annual Meeting of the International Continence Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top